Unsafe
Not Aligned
Patient Risk:
High
Summary
Several key claims introduce specific adverse-effect and interaction mechanisms (notably blood-pressure decrease with blood-pressure medications, ACEi/ARB-related cognitive impairment, confusion/disorientation, falls, nausea, organ failure) that are not supported by the provided FDA label sections. Indication-related and dizziness/edema-related statements are only partially supported, but the interaction theories create major label misalignment.
Category Scores
Accurate Statements
Lyrica (pregabalin) is used to treat nerve pain.
Indicated for management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia, and neuropathic pain associated with spinal cord injury (1 INDICATIONS AND USAGE).
Lyrica (pregabalin) is used to treat epilepsy.
Indicated as adjunctive therapy for partial-onset seizures in patients 1 month of age and older (1 INDICATIONS AND USAGE).
Pregabalin can cause dizziness, lightheadedness, or fainting.
LYRICA may cause dizziness and somnolence (5.5 Dizziness and Somnolence). (Lightheadedness/fainting not explicitly supported in the provided sections.)
Pregabalin can increase fluid retention.
LYRICA treatment may cause peripheral edema (5.7 Peripheral Edema). (The term 'fluid retention' is not explicitly used in the provided sections.)
Increased fluid retention may worsen congestive heart failure.
Caution that thiazolidinediones can cause weight gain and/or fluid retention possibly exacerbating or leading to heart failure (5.7 Peripheral Edema). (Not specifically stated that pregabalin fluid retention worsens CHF; label frames caution with TZDs.)
Unsupported Statements
Lyrica (pregabalin) is used to treat anxiety disorders.
No anxiety disorder indication is listed in the provided label section (1 INDICATIONS AND USAGE).
Pregabalin can decrease blood pressure.
No provided label statement supports pregabalin decreasing blood pressure.
Pregabalin can cause dizziness, lightheadedness, or fainting especially when taken with other blood pressure medications.
Provided sections discuss dizziness/somnolence but do not describe a blood-pressure-medication-specific interaction.
Increased fluid retention may exacerbate edema in patients taking blood pressure medications.
Provided caution in 5.7 is about thiazolidinediones and does not state a relationship involving blood pressure medications.
The combination of Lyrica and blood pressure medications can lead to a significant drop in blood pressure.
No provided label statement supports significant blood pressure drop from combining pregabalin with blood pressure medications.
A significant drop in blood pressure can cause dizziness.
Provided label supports dizziness, but does not link it to blood pressure drops.
A significant drop in blood pressure can cause nausea.
No provided label statement links blood pressure decreases to nausea.
A significant drop in blood pressure can cause organ failure in severe cases.
No provided label statement describes organ failure resulting from blood pressure decreases.
Some blood pressure medications, such as ACE inhibitors and ARBs, can impair cognitive function when taken with Lyrica.
No provided label statement mentions ACE inhibitors/ARBs or cognitive impairment interactions with pregabalin.
Impaired cognitive function from Lyrica with ACE inhibitors or ARBs may cause confusion.
No provided label statement supports this ACEi/ARB-specific cognitive adverse-effect claim.
Impaired cognitive function from Lyrica with ACE inhibitors or ARBs may cause disorientation.
No provided label statement supports this ACEi/ARB-specific cognitive adverse-effect claim.
Impaired cognitive function from Lyrica with ACE inhibitors or ARBs may cause decreased alertness.
No provided label statement supports this ACEi/ARB-specific cognitive adverse-effect claim.
Older adults may be more likely to experience dizziness from the interaction.
The provided geriatric section notes certain neurologic adverse reactions more frequently in older adults in specific trials, but does not attribute this to an interaction with blood pressure medications.
Older adults may be more likely to experience falls from the interaction.
No provided label statement supports falls related to an interaction.
Older adults may be more likely to experience cognitive impairment from the interaction.
The provided geriatric section lists neurologic adverse reactions more frequent in older adults (e.g., confusional state) but does not attribute cognitive impairment to a blood pressure-medication interaction.
Patients with pre-existing cardiovascular conditions are at a higher risk of experiencing serious complications from the interaction.
No provided label statement supports this interaction-based risk framing.
Patients with high blood pressure are at a higher risk of experiencing serious complications from the interaction.
No provided label statement supports this.
Patients with kidney disease are at a higher risk of experiencing serious complications from the interaction.
The provided geriatric section discusses increased risk of toxic reactions with impaired renal function generally, but does not support a blood pressure-medication interaction framing or 'serious complications from the interaction.'
Taking multiple medications, especially blood pressure medications and opioids, increases the risk of adverse interactions involving Lyrica.
Provided drug interaction section emphasizes low likelihood of metabolic/protein-binding interactions with certain antiepileptics; it does not support opioid- and blood-pressure-medication-specific interaction risk claims in the provided text.
Contradictions
Important Omissions
No label-supported contraindication, boxed warning, or full warnings/precautions context was provided while making extensive interaction and serious-outcome claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple claims present specific interaction effects and serious outcomes (e.g., significant blood pressure drops, nausea, organ failure; ACEi/ARB cognitive impairment; falls) that are not supported by the provided label sections, which could mislead clinicians/users about real labeled risks.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Unsupported and overly specific blood-pressure/ACEi/ARB interaction mechanisms and serious outcome claims not present in the provided label sections.
Suggested Improvement
Limit claims to label-supported indications and the provided label-supported adverse effects (e.g., dizziness/somnolence; peripheral edema; caution around TZDs and heart failure) and avoid asserting blood-pressure-medication-specific interactions, ACEi/ARB cognitive impairment interactions, falls, nausea, or organ failure unless explicitly supported by the FDA label.